Phase II Evaluation of Ly156758 in Metastatic Breast Cancer

Oncology. 1988;45(5):344-5. doi: 10.1159/000226637.

Abstract

Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treated with tamoxifen therapy.

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Drug Evaluation
  • Estrogen Antagonists / therapeutic use*
  • Female
  • Humans
  • Neoplasm Metastasis
  • Piperidines / therapeutic use*
  • Raloxifene Hydrochloride

Substances

  • Estrogen Antagonists
  • Piperidines
  • Raloxifene Hydrochloride